Daniel Oh, MD
Retina Specialist · Atlanta, GANPI 1619324555
Payments from drug & device makers
What this record shows
This record is dominated by grants: $49,999 of the $57,663 with a category attached, or 86.7%. Regeneron accounts for 86.7% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2021 at $28,312 and has fallen 96.5% since, to $977 in 2025.
Across 160 payments — averaging $360.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$50K
- Notal Vision, Inc.$1K
- Eyepoint US, Inc.$1K
- Regeneron Healthcare Solutions, Inc.$883
- Genentech USA, Inc.$870
- Astellas Pharma US Inc$804
- plus $3K from 10 others
Across 24 payments — averaging $80.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$1K
- Notal Vision, Inc.$570
What the payments were for
- Consulting fees$9002%
- Speaking & faculty fees$1,7703%
- Grants$49,99987%
- Food & beverage$4,9949%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 25 | $49,999 |
| Notal Vision, Inc. | 3 | $1,420 |
| Eyepoint US, Inc. | 2 | $1,025 |
| Regeneron Healthcare Solutions, Inc. | 24 | $883 |
| Genentech USA, Inc. | 17 | $870 |
| Astellas Pharma US Inc | 17 | $804 |
| Alimera Sciences, Inc. | 11 | $736 |
| Apellis Pharmaceuticals, Inc. | 16 | $698 |
| AbbVie | 24 | $511 |
| ANI Pharmaceuticals, Inc. | 9 | $215 |
| Bausch & Lomb Americas Inc. | 2 | $165 |
| Rxsight Inc | 1 | $125 |
| Sandoz | 5 | $113 |
| Stimwave Technologies Incorporated | 2 | $53 |
| Alcon | 1 | $29 |
| Coherus Oncology, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few retina specialist providers in Georgiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 160 | $6,160 |
| Brimonidine Tartrate | 35 | $2,542 |
| Atropine Sulfate | 50 | $1,486 |
| Ketorolac Tromethamine | 26 | $986 |
| Latanoprost | 55 | $765 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 65 | $541 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 54 | $365 |
| Ciprofloxacin Hcl | 33 | $327 |
| Dorzolamide Hcl | 14 | $138 |
| Cyclopentolate Hcl | 12 | $74 |
| Timolol Maleate | 20 | $68 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Atlanta
- David Chin YeeAtlanta$816K
- Sruthi ArepalliAtlanta$30K
- James FrankAtlanta$4K
- Nihaal MehtaAtlanta$468
- Ranjit DhaliwalAugusta$18K
- Oksana DemediukAugusta$16K
- Alexander BottiniBraselton$7K
- Kareem SioufiMarietta$6K
- Dimple ModiRome$3K
- Sohail KhanAugusta$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.